Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory ...

In the United States, the biomedical industry encounters numerous regulatory challenges in conducting nonclinical and ...

Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

Bushra Sumra's career highlights the profound impact that expertise in clinical research and regulatory compliance can have on advancing treatments for rare diseases.

The proposed guidance aims to provide a framework for the approval of personalised mRNA-based cancer vaccines.

The Budget Estimates (BE) for the Centrally Sponsored Scheme of Strengthening of States Drug Regulatory System (SSDRS) for the fiscal year 2025-26 is Rs. 50 crore, around 33 per cent less than the ...

Over 400 enforcement actions, including show cause notices, production stoppages, and license cancellations, have been taken ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced receipt of revised ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...